Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anixa Biosciences, Inc. filings document regulatory disclosures for a cancer-focused biotechnology company developing vaccine and CAR-T therapy programs. Recent Form 8-K reports include Regulation FD disclosures on the company's ovarian cancer CAR-T program, lira-cel, and its investigational breast cancer vaccine, including related press releases and scientific-presentation exhibits.
The company's proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, common-stock voting results, and other governance matters. These filings provide the formal record for Anixa's public-company reporting around clinical-program updates, stockholder actions, and corporate oversight.
Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased additional Common Stock in the company. On September 10, 2026, he bought 3,000 shares in an open-market or private transaction at $2.75 per share, bringing his directly held stake to 665,000 shares. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. reported purchasing 10,000 shares of common stock on September 10, 2026 in an open-market or private transaction at $2.73 per share. Following this purchase, he directly holds 996,967 shares of Anixa Biosciences common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on September 10, 2026 at $2.76 per share in an open-market or private transaction. Following this purchase, he directly owns 662,000 shares of Anixa common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences, Inc. (ANIX) reported another development-stage quarter for the period ended July 31, 2026, with no revenue and a net loss attributable to common shareholders of $2.6 million for the quarter and $7.7 million for the nine months. Total operating expenses for the nine months were $8.1 million, down modestly from $8.8 million a year earlier, as research and development and general and administrative costs both declined, largely from lower stock-based compensation.
Total assets were $15.1 million, including $13.9 million in cash, cash equivalents and short-term investments, compared with $15.2 million at October 31, 2025. Net cash used in operating activities was $6.1 million for the nine months, partly offset by $4.8 million raised via an at-the-market equity offering. Anixa states that existing cash, cash equivalents and short-term investments are expected to fund operations for at least the next twelve months and for significantly longer than 12 months under its current plans.
Operationally, the company continues advancing its CAR-T ovarian cancer therapy and breast and ovarian cancer vaccine programs, with a Phase 1 CAR-T trial treating higher-dose cohorts and a completed Phase 1 breast cancer vaccine trial showing met primary endpoints and observed immune responses. Preparation is under way for a Phase 2 breast cancer vaccine trial.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock in an open-market transaction on July 31, 2026, at $3.47 per share. After this purchase, he directly holds 657,000 shares of Anixa Biosciences common stock.
Arnold M. Baskies, a director of Anixa Biosciences Inc, exercised employee stock options covering 6,000 shares of common stock on July 27, 2026 at an exercise price of $3.1300 per share. These options were granted on August 23, 2013 and were approaching expiration on August 23, 2026.
To cover the option exercise cost, 5,428 shares of common stock were withheld by Anixa Biosciences Inc at $3.4600 per share. Following this exercise, the related stock option position reported for this grant was reduced to 0 derivative securities.
Amit Kumar, Chief Executive Officer and director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 27, 2026 in a transaction reported as a purchase in open market or private transaction at $3.44 per share, bringing his directly held stake to 652,000 shares.
Anixa Biosciences Inc reported that Chief Executive Officer Amit Kumar purchased 3,188 shares of Common Stock on July 27, 2026, at $3.37 per share in a purchase in open market or private transaction. Following this transaction, he directly holds 647,000 shares.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 3,000 shares of Common Stock on July 24, 2026 at $3.73 per share in an open-market or private transaction. Following this trade, his directly held position increased to 643,812 shares of Anixa Biosciences Inc common stock.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on 2026-07-20 at $3.46 per share in an open-market or private transaction. Following this buy, he directly owns 640,812 shares. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.